These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 23083822)

  • 1. Approach to the treatment-naïve patient with HCV genotype 1 infection.
    Muir AJ
    Infect Dis Clin North Am; 2012 Dec; 26(4):893-901. PubMed ID: 23083822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection.
    Flemming JA; Terrault NA
    Infect Dis Clin North Am; 2012 Dec; 26(4):903-15. PubMed ID: 23083823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
    Silva MO; Treitel M; Graham DJ; Curry S; Frontera MJ; McMonagle P; Gupta S; Hughes E; Chase R; Lahser F; Barnard RJ; Howe AY; Howe JA
    J Hepatol; 2013 Jul; 59(1):31-7. PubMed ID: 23454058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic hepatitis C].
    Grammatikos G; Sarrazin C
    Dtsch Med Wochenschr; 2010 Dec; 135(50):2525-34; quiz 2535-8. PubMed ID: 21140330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.
    Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
    J Med Virol; 2013 Jan; 85(1):65-70. PubMed ID: 23154876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
    Jacobson IM; Pawlotsky JM; Afdhal NH; Dusheiko GM; Forns X; Jensen DM; Poordad F; Schulz J
    J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Trembling PM; Tanwar S; Dusheiko GM
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment.
    Gerner P; Hilbich J; Wenzl TG; Behrens R; Walther F; Kliemann G; Enninger A; Wirth S
    J Pediatr Gastroenterol Nutr; 2010 Aug; 51(2):187-90. PubMed ID: 20512050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy.
    Lontok E; Mani N; Harrington PR; Miller V
    Clin Infect Dis; 2013 May; 56(10):1466-70. PubMed ID: 23362287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs in development for chronic hepatitis C: a promising future.
    Pockros PJ
    Expert Opin Biol Ther; 2011 Dec; 11(12):1611-22. PubMed ID: 21995412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the management of hepatitis C.
    Croagh CM; Lubel J
    Intern Med J; 2013 Dec; 43(12):1265-71. PubMed ID: 24330361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of HCV RNA measurement for tailoring treatment duration.
    Peiffer KH; Sarrazin C
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S323-31. PubMed ID: 24091111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus drug resistance: implications for clinical management.
    Wyles DL
    Infect Dis Clin North Am; 2012 Dec; 26(4):967-78. PubMed ID: 23083827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparing the patient for success: treat or wait?
    Buti M; Esteban R
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S332-6. PubMed ID: 24091112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New combination attains a response rate of 90].
    Warpakowski A
    MMW Fortschr Med; 2015 Sep; 157(15):71. PubMed ID: 26349741
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapid and sharp decline in HCV upon monotherapy with NS3 protease inhibitor, ACH-1625.
    Agarwal A; Zhang B; Olek E; Robison H; Robarge L; Deshpande M
    Antivir Ther; 2012; 17(8):1533-9. PubMed ID: 22976492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach.
    Sherman KE
    Clin Infect Dis; 2012 Nov; 55(9):1236-41. PubMed ID: 22843782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.